Rapport Therapeutics (NASDAQ:RAPP - Get Free Report)'s stock had its "market outperform" rating reissued by equities research analysts at JMP Securities in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $28.00 price objective on the stock. JMP Securities' target price indicates a potential upside of 121.87% from the stock's previous close.
Separately, Citizens Jmp started coverage on Rapport Therapeutics in a research note on Tuesday, April 8th. They issued a "mkt outperform" rating on the stock.
Check Out Our Latest Report on Rapport Therapeutics
Rapport Therapeutics Stock Performance
Rapport Therapeutics stock traded up $0.58 during trading hours on Tuesday, reaching $12.62. 143,261 shares of the company's stock traded hands, compared to its average volume of 164,815. Rapport Therapeutics has a fifty-two week low of $6.43 and a fifty-two week high of $29.74. The firm has a market capitalization of $460.63 million and a price-to-earnings ratio of -3.66. The firm's 50 day moving average is $11.02 and its 200-day moving average is $12.16.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.09. Analysts predict that Rapport Therapeutics will post -3.65 EPS for the current year.
Institutional Investors Weigh In On Rapport Therapeutics
Several institutional investors have recently modified their holdings of RAPP. TRV GP V LLC purchased a new position in Rapport Therapeutics during the 4th quarter valued at approximately $126,579,000. TRV GP VI LLC acquired a new position in shares of Rapport Therapeutics during the 4th quarter worth approximately $17,194,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC acquired a new position in Rapport Therapeutics in the 1st quarter valued at $2,039,000. Price T Rowe Associates Inc. MD increased its stake in shares of Rapport Therapeutics by 9.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,143,384 shares of the company's stock worth $20,285,000 after acquiring an additional 95,976 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Rapport Therapeutics during the 4th quarter worth $860,000.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Articles
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
